{
  "dataset": "eval/testset.sample.jsonl",
  "examples": [
    {
      "answer": "Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 assessed within 7 days before randomization.",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT06556563",
          "section": "eligibility.inclusion",
          "text_snippet": "1. The participant (or legally acceptable representative) has provided documented informed consent for the study. 2. Be \u2265 18 years of age on day of providing informed consent. 3. Participant with new diagnosis of GBM according to World Health Organization (WHO) 2021 Classification. 4. Recovered from maximal debulking surgery (gross total resection, partial resection and biopsy-only patients are all acceptable), Gliadel wafers placement at the time of surgical resection is not allowed. 5. Have completed standard adjuvant chemoradiotherapy of radiotherapy (RT) according to local practice (56-64 Gy), and concomitant TMZ chemotherapy. 6. Amenable to treatment with Optune concomitant with maintenance TMZ (150-200 mg/m\\^2 daily x 5, Q28 days). 7. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 assessed within 7 days before randomization. 8. Stable or decreasing dose of corticosteroids (dexamethasone \u2264 2mg or equivalent) for the last 7 days prior to randomization, if applicable."
        },
        {
          "nct_id": "NCT06556563",
          "section": "eligibility.exclusion",
          "text_snippet": "1. Has received prior therapy with an anti-Programmed Cell Death 1 (PD-1), anti- Programmed Cell Death-Ligand 1(PD-L1), or anti Programmed Cell Death-Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4), OX 40, CD137). 2. Ongoing requirement for \\>2 mg dexamethasone (or equivalent), due to intracranial mass effect. 3. Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to randomization. 4. Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed. 5. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first study treatment. 6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. 7. Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. 8. Early progressive disease after the end of TMZ/RT. If pseudo progression is suspected, additional imaging studies should be performed to rule out true progression. 9. Infratentorial or leptomeningeal disease."
        },
        {
          "nct_id": "NCT06556563",
          "section": "title",
          "text_snippet": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune\u00ae (TTFields, 200 kHz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune\u00ae Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58)."
        }
      ],
      "expected_sections": [
        "eligibility.inclusion"
      ],
      "gold_answers": [
        "Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 assessed within 7 days before randomization."
      ],
      "nct_id": "NCT06556563",
      "query": "What ECOG performance status must participants have for trial NCT06556563?",
      "status_code": 200
    },
    {
      "answer": "Measurable disease (bidimensional) as defined by the RANO criteria, with a minimum measurement of 1 cm in longest diameter on MRI performed within 21 days of first dose of acalabrutinib;",
      "answer_exact_match": false,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT02586857",
          "section": "eligibility.inclusion",
          "text_snippet": "Men and women \u226518 years of age Histologically confirmed GBM at first or second recurrence after concurrent or adjuvant chemotherapy or radiotherapy (must have received temozolomide). Radiographic demonstration of disease progression by MRI following prior therapy. Measurable disease (bidimensional) as defined by the RANO criteria, with a minimum measurement of 1 cm in longest diameter on MRI performed within 21 days of first dose of acalabrutinib; MRI must have been obtained \u22654 weeks after any salvage surgery after first or second relapse. Stable or decreasing dose of corticosteroids \u22655 days before baseline MRI (at study entry). On a stable dose of any required therapy (such as anticonvulsant medication for subjects to be enrolled into the Phase 1b portion), for \u22653 weeks before the first dose of acalabrutinib. Eastern Cooperative Oncology Group (ECOG) performance status of \u22642. Life expectancy \u2265 12 weeks. Completion of all prior anticancer therapy before first ACP-196 dose. Need to have recovered (i.e., Grade \u22641 or baseline) from AEs associated with prior cancer therapy. Note: Subjects with Grade \u22642 neuropathy or Grade 2 alopecia are an exception, and may qualify for the study."
        },
        {
          "nct_id": "NCT02586857",
          "section": "eligibility.exclusion",
          "text_snippet": "Three or more prior lines of systemic therapy for GBM. Prior malignancy (other than GBM), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for \u22652 years. Any cases of prior malignancy allowed on study are to be approved by the study medical monitor. Significant cardiovascular disease. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass. Evidence of bleeding diathesis or coagulopathy. Requires urgent palliative intervention for primary disease Requires treatment with a strong CYP3A4 inhibitor.. History of stroke or clinically significant intracranial hemorrhage within 6 months before first dose of study drug. Breastfeeding or pregnant. Subjects previously treated with bevacizumab (Avastin)"
        },
        {
          "nct_id": "NCT02586857",
          "section": "outcomes",
          "text_snippet": "{'measure': 'Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.', 'time_frame': 'On Cycle 3 Day 1, Cycle 4 Day 1 (4 weeks after Cycle 3 Day 1 scan to evaluate for response stability), then on Day 1 of every other cycle (every 8 weeks) thereafter (e.g., Cycle 6 Day 1, Cycle 8 Day 1)'}"
        },
        {
          "nct_id": "NCT02586857",
          "section": "title",
          "text_snippet": "A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)"
        }
      ],
      "expected_sections": [
        "eligibility.inclusion"
      ],
      "gold_answers": [
        "Measurable disease (bidimensional) as defined by the RANO criteria, with a minimum measurement of 1 cm in longest diameter on MRI performed within 21 days of first dose of acalabrutinib; MRI must have been obtained \u22654 weeks after any salvage surgery after first or second relapse."
      ],
      "nct_id": "NCT02586857",
      "query": "What measurable disease requirement does NCT02586857 enforce?",
      "status_code": 200
    },
    {
      "answer": "Patient on low molecular weight heparins, standard unfractionated heparins and anti-vitamin K2",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT06051214",
          "section": "eligibility.exclusion",
          "text_snippet": "1. Patient who has had a VTE in the 12 months preceding the diagnosis of cancer, 2. Patient on low molecular weight heparins, standard unfractionated heparins and anti-vitamin K2, 3. Women who are pregnant, likely to become pregnant or who are breast-feeding, 4. Persons deprived of their liberty, under court protection, under curators or under the authority of a guardian, 5. Unable to undergo medical monitoring of the trial for geographical, social or psychological reasons."
        },
        {
          "nct_id": "NCT06051214",
          "section": "title",
          "text_snippet": "Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients At Risk"
        },
        {
          "nct_id": "NCT06051214",
          "section": "eligibility.inclusion",
          "text_snippet": "1. Patient aged \\> 18 years, 2. Patient with a solid cancer at high risk of thrombosis, whether metastatic or not (lung, pancreatic, gastric or glioblastoma cancers)1, 3. Patients who have not received any systemic treatment for their cancer, 4. An informed patient who does not object to the use of data for research purposes and who has consented to the collection, use and storage of biological samples."
        }
      ],
      "expected_sections": [
        "eligibility.exclusion"
      ],
      "gold_answers": [
        "Patient on low molecular weight heparins, standard unfractionated heparins and anti-vitamin K2"
      ],
      "nct_id": "NCT06051214",
      "query": "Which anticoagulant therapies exclude someone from NCT06051214?",
      "status_code": 200
    },
    {
      "answer": "at least 2 biopsy samples",
      "answer_exact_match": false,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT05386043",
          "section": "eligibility.inclusion",
          "text_snippet": "1. Subject is between 18 and 89 years of age. 2. Subject has radiologically-diagnosed or suspected WHO Grade II-IV glioma based on physician review or conformance with published WHO criteria as evaluated by the PI\\*. 3. Subject is treatment-na\u00efve with the exception of previous biopsy for the above condition. 4. Subject is planning to undergo surgical resection and biopsy of their brain tumor. 5. Subject has sufficient tissue so that the study team is able to acquire at least 2 biopsy samples during resection. 6. Subject is able to read and write in English. 7. Subject is able to lay supine for up to 80 minutes. 8. Subject is able to hold still during MRI procedures. 9. Subject or their LAR has signed the consent form for participation in the study."
        },
        {
          "nct_id": "NCT05386043",
          "section": "eligibility.exclusion",
          "text_snippet": "1. Subject has conditions that would preclude the completion of an MRI such as claustrophobia, pacemaker, metal objects in the body, and/or pregnancy. 2. Subject has serious unstable medical or mental illness. 3. Subject has insufficient tissue to acquire at least two biopsy samples during resection. 4. Subject has a medical contraindication to any element of the study procedures. 5. Subject or their LAR has not read and signed the informed consent form, or does not understand its contents. 6. Subject is pregnant.\\*\\* 7. Subject is at high risk for NSF (eGFR\\<60 or serum creatine \\>1.3) and cannot follow the weight-based dosing protocol for Gadavist.\\*\\*\\*"
        },
        {
          "nct_id": "NCT05386043",
          "section": "interventions",
          "text_snippet": "DRUG: FET F-18 DRUG: O-15 Radioisotope PROCEDURE: CT scan PROCEDURE: MRI with gadolinium-based contrast PROCEDURE: Biopsy Collection"
        }
      ],
      "expected_sections": [
        "eligibility.inclusion"
      ],
      "gold_answers": [
        "Subject has sufficient tissue so that the study team is able to acquire at least 2 biopsy samples during resection."
      ],
      "nct_id": "NCT05386043",
      "query": "How many biopsy samples must be obtainable during surgery in NCT05386043?",
      "status_code": 200
    },
    {
      "answer": "WP1066",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT05879250",
          "section": "eligibility.inclusion",
          "text_snippet": "Newly diagnosed, histologically confirmed World Health Organization (WHO) glioblastoma multiforme (GBM), IDH wild-type External pathology reports are permitted for confirmation of histological diagnosis Documentation of isocitrate dehydrogenase (IDH) wild-type status will be by IDH1 R123H immunohistochemistry, except for patients =\\< age 54 for whom IDH sequencing will be required to detect noncanonical IDH mutations Documentation of O6-methylguanine-DNA methyltransferase (MGMT) unmethylated status per testing at any Clinical Laboratory Improvement Amendment (CLIA) certified laboratory Cohort 1 only: Patients with prior gross total resection (GTR) Cohort 2 only: Patients without prior gross total resection (GTR) Cohort 2 only: Measurable disease in the brain (per RANO criteria) on brain magnetic resonance imaging (MRI) scan conducted within =\\< 4 weeks prior to initiating trial therapy Cohort 2 only: Patients who would benefit from non-emergent, palliative surgical resection, in the opinion of the local site's tumor board Able to initiate trial therapy within 8 weeks of the initial brain surgical procedure (biopsy or resection) that lead to the patient's initial diagnosis of GBM Age \\>=18 years Karnofsky performance scale score \\>= 60% White blood cell (WBC) count \\>= 3.0 x 10\\^9/L (within =\\< 30 days prior to registration) (without growth factor support and/or receipt of blood products within =\\< 14 days prior to testing) Absolute neutrophil count (ANC) \\>= 1.0 x 10\\^9/L (within =\\< 30 days prior to registration) (without growth factor support and/or receipt of blood products within =\\< 14 days prior to testing) Platelet count \\>= 75 x 10\\^9/L (within =\\< 30 days prior to registration) (without growth factor support and/or receipt of blood products within =\\< 14 days prior to testing) Total bilirubin =\\< 1.5 x upper limit of normal (ULN) or direct bilirubin =\\< ULN for subjects with total bilirubin levels \\> 1.5 x ULN (within =\\< 30 days prior to registration) Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) =\\< 2.5 x ULN (within =\\< 30 days prior to registration) Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) =\\< 2.5 x ULN (within =\\< 30 days prior to registration) Creatinine or creatinine clearance within normal institutional limits. A creatinine level above the institutional normal limit is acceptable, provided creatinine clearance (CrCl) is \\>= 60 mL/min/1.73 m\\^2 (within =\\< 30 days prior to registration). Creatinine clearance should be calculated using the Cockcroft-Gault formula International normalized ratio (INR) =\\< 1.5 x ULN or for subjects receiving anticoagulant therapy, INR must be within the therapeutic range of intended use of anticoagulants, as determined by the treating investigator (within =\\< 30 days prior to registration) Activated partial thromboplastin time (aPTT) =\\< 1.5 x ULN or for subjects receiving anticoagulant therapy, aPTT must be within the therapeutic range of intended use of anticoagulants, as determined by the treating investigator (within =\\< 30 days prior to registration) Willing and able to tolerate brain MRI with contrast. Patients with any known severe allergy to contrast agent(s) should not participate in the study. Patients with mild allergies to contrast agents (e.g., rash only) may participate in the study per treating investigator discretion; it is recommended that these patients be pretreated with acetaminophen and diphenhydramine \\[or other institutional standard combination of agent(s) for allergy prep\\] prior to injection of the contrast agent Willing and able to follow the below contraception requirements: For Females: Female subjects of childbearing potential (defined below) must agree to use adequate contraception (e.g., abstinence or 2 methods of birth control, such as a barrier method in combination with hormonal contraception) starting from the time of informed consent, throughout the duration of treatment with WP1066, and for 2 months after the last dose of WP1066. They also must agree to not donate/freeze eggs during the same timeframe. A female of reproductive potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets both of the following two criteria: Has not undergone a hysterectomy or bilateral oophorectomy Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months) For Males: Male subjects must agree to use adequate contraception (e.g., abstinence or 2 methods of birth control, such as a barrier method in combination with partner's use of"
        },
        {
          "nct_id": "NCT05879250",
          "section": "eligibility.exclusion",
          "text_snippet": "Receipt of investigational agents within =\\< 2 weeks prior to registration Prior receipt of gene therapy, at any time Prior receipt of bevacizumab, at any time Prior receipt of Gliadel, at any time Patients who are on active therapy with Optune and who are unable to safely discontinue Optune prior to initiating trial therapy Note: Patients who can safely discontinue Optune prior to initiating trial therapy may participate Patients who are on active therapeutic anti-cancer therapy and who are unable to discontinue the anti-cancer therapy prior to initiating trial therapy Note: Patients who discontinue anti-cancer therapy prior to initiating trial therapy may participate. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen for this trial may participate History of allergic reactions attributed to compounds of similar chemical or biologic composition to WP1066 or its excipients Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy Note: These patients are ineligible because of the potential for pharmacokinetic interactions with WP1066. (HIV testing is not required, unless mandated by a local health authority.) Patients who have received drugs that significantly interact with CYP450 enzyme(s) within =\\< 2 weeks prior to planned first study treatment day Note: Patients who are able to safely discontinue the aforementioned agents \\> 2 weeks prior to initiating treatment with WP1066 may participate. The enzymatic metabolism profile of WP1066 is unknown. Drugs that have a minor interaction with CYP450 are allowed, and drugs with a moderate interaction are allowed at the principal investigators (PI's) discretion. Zofran (ondansetron) is allowed Patients who have received any of the following agents within 7 days of planned first study treatment day: Agents that are predominantly CYP2D6, 2C9, or 2C19 substrates Agents that are strong inhibitors or inducers of CYP2D6, 2C9, or 2C19 Agents that are sensitive substrates of CYP3A4 with narrow therapeutic range Note: Patients who are able to safely discontinue the aforementioned agents \\> 7 days prior to initiating treatment with WP1066 may participate. The enzymatic metabolism profile of WP1066 is unknown. Drugs that are minor CYP2D6, 2C9 or 2C19 substrates; minor inhibitors or inducers of CYP2D6, 2C9, or 2C19; or minor substrates of CYP3A4 are allowed. Moderate drugs will be allowed per PI's discretion. Zofran (ondansetron) is allowed Patients on corticosteroids who require escalation of the corticosteroid dose Note: Patients receiving a stable or decreasing dose for at least one week may participate. Zofran (ondansetron) is allowed History of brain hemorrhage, unless the following exception is met: Exception: Small, asymptomatic brain hemorrhage may be permitted, provided written documentation of PI approval has been obtained Note: The potential for further hemorrhaging with the use of WP1066 is unknown. It will be at the PIs discretion to enroll a patient who has a small, asymptomatic brain hemorrhage, but patients who have had symptomatic hemorrhages will be excluded Uncontrolled seizures or seizure requiring escalation or addition of anti-epileptic drug Lesion(s) larger than 50 mm in maximal diameter on MRI, or with midline shift exceeding 5 mm, or with hydrocephalus Diffuse leptomeningeal disease Note: Because one of the objectives is PFS based on radiographic volumetric analysis of the tumor, the presence of diffuse leptomeningeal disease is excluded. This is secondary to the inadequacy of measuring the extent of the tumor burden within this setting and the very poor prognosis of these patients Corrected QT (QTc) B interval \\>= 450 ms These patients are excluded because the cardiac toxicities of WP1066 are unknown. Concomitant use of agents that prolong the QT interval should be avoided whenever feasible, or used with caution. Zofran (ondansetron) is allowed Subjects who are at increased risk for radiation therapy (RT)-associated toxicities, such as those with known active collagen vascular disease (e.g., scleroderma, Sjogren's disease, etc.) or other inherited RT-hypersensitivity syndromes (e.g., Gorlin syndrome, Fanconi anemia, ataxia-telangiectasia, etc.) For female patients of childbearing potential only: Patients with a positive serum beta-human chorionic gonadotropin (HCG) pregnancy test within =\\< 2 days prior to planned start date for trial therapy or who are immediately planning to become pregnant Breastfeeding patients who are unwilling/unable to discontinue breastfeeding while receiving WP1066 Note: Because there is an"
        },
        {
          "nct_id": "NCT05879250",
          "section": "eligibility.inclusion",
          "text_snippet": "hormonal contraception) starting from the time of informed consent, throughout the duration of treatment with WP1066, and for 4 months after the last dose of WP1066. They also must agree to not donate sperm during the same timeframe Note: The effects of WP1066 on the developing human fetus are unknown. WP1066 could potentially be teratogenic or have abortifacient effects. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately Subject (or subject's legally authorized representative if subject has impaired decision-making capacity) must have the ability to understand and the willingness to sign a written informed consent document Both men and women of all races and ethnic groups may participate in this trial"
        },
        {
          "nct_id": "NCT05879250",
          "section": "interventions",
          "text_snippet": "PROCEDURE: Biospecimen Collection PROCEDURE: Magnetic Resonance Imaging RADIATION: Radiation Therapy DRUG: STAT3 Inhibitor WP1066 PROCEDURE: Surgical Procedure"
        },
        {
          "nct_id": "NCT05879250",
          "section": "title",
          "text_snippet": "A Multi-Arm, Open Label, Phase II Trial of WP1066 and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma"
        }
      ],
      "expected_sections": [
        "interventions"
      ],
      "gold_answers": [
        "STAT3 Inhibitor WP1066",
        "WP1066"
      ],
      "nct_id": "NCT05879250",
      "query": "Name the STAT3-targeting drug administered in NCT05879250.",
      "status_code": 200
    },
    {
      "answer": "MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients With Tumors With BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations",
      "answer_exact_match": false,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT06400225",
          "section": "eligibility.inclusion",
          "text_snippet": "Patients must have met applicable eligibility criteria in the Master MATCH Protocol EAY131/ NCI-2015-00054 prior to registration to treatment subprotocol Patients must fulfill all eligibility criteria of MATCH Master Protocol at the time of registration to treatment step (Step 1, 3, 5, 7) Patients must have a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration, as determined via the MATCH Master Protocol Patients with BRAF V600E/K/R/D mutations are excluded Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block) Patients must not have known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to BVD-523FB (ulixertinib), dimethyl sulfoxide (DMSO), or excipients Patients must not have a left ventricular ejection fraction (LVEF) \\< the institutional lower limit of normal (LLN) or \\< 50% (whichever is higher) Patients must not have prior use of MEK or ERK 1/2 inhibitors Patients must not have a history of retinal vein occlusion (RVO) or central serous retinopathy. Patients with visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for retinal vein thrombosis or central serous retinopathy will be excluded Intraocular pressure is \u2264 21mm Hg as measured by tonography. Patients diagnosed with glaucoma within 1 month prior to Step 1 registration are excluded Patients must not have leptomeningeal metastases or spinal cord compression due to disease Patients must not have primary malignancy of the central nervous system"
        },
        {
          "nct_id": "NCT06400225",
          "section": "title",
          "text_snippet": "MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients With Tumors With BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations"
        },
        {
          "nct_id": "NCT06400225",
          "section": "condition",
          "text_snippet": "Advanced Lymphoma Advanced Malignant Solid Neoplasm Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Multiple Myeloma"
        }
      ],
      "expected_sections": [
        "eligibility.inclusion"
      ],
      "gold_answers": [
        "Patients must have a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration, as determined via the MATCH Master Protocol"
      ],
      "nct_id": "NCT06400225",
      "query": "Which BRAF alterations qualify participants for MATCH subprotocol Z1L (NCT06400225)?",
      "status_code": 200
    },
    {
      "answer": "Patients must have at least 15 slides without staining or a tissue block (frozen or paraffin-embedded) available from a previous biopsy or surgery (tumour sample previously archived).",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT03529448",
          "section": "eligibility.inclusion",
          "text_snippet": "Ability to understand and sign the informed consent document Men or women \u226518 years and \u226470 years Newly-diagnosed GB confirmed by biopsy or by resection in the 4-7 weeks before being registered in the trial. Patients must have at least 15 slides without staining or a tissue block (frozen or paraffin-embedded) available from a previous biopsy or surgery (tumour sample previously archived). Patients must have recovered from previous surgeries (time between surgery and inclusion in the study: 6 weeks). Karnofsky Index \u226560%. Adequate bone marrow reserve: haemoglobin \u226510 g/dL, WBC \\>3,000/mcL, absolute neutrophil count (ANC) \u22651,500 cells/\u03bcL, platelets \u2265100,000 cells/\u03bcL. Adequate liver function: Bilirubin \\<1.5 times the upper limit of normal (ULN); AST \u22642.5 x ULN Creatinine clearance \\>60 ml/min/1.73 m2. The study treatment's effects on the development of the human foetus are not known. For this reason, women of childbearing age and men must agree to use a suitable birth control method (hormonal, barrier, abstinence or surgical sterilisation) before inclusion in the study, for the duration of the study and for at least 3 months after completing the trial treatment. The definition of an effective method of birth control is based on the judgement of the principal investigator or their designee. If a woman is pregnant or there is suspicion that she might be pregnant while participating in the study, she must inform the trial doctor immediately. All women of childbearing age should have a negative pregnancy test (serum/urine) in the 2 weeks prior to the beginning of treatment."
        },
        {
          "nct_id": "NCT03529448",
          "section": "eligibility.exclusion",
          "text_snippet": "Presence of extracranial metastatic disease. Any previous treatment for glioblastoma. Patients who have had a Gliadel implant in the surgery. Use of an enzyme-inducing antiepileptic drug. Patients receiving this type of drug must have a washout period of at least 7 days prior to study inclusion. Previous abuse of cannabinoids. Presence of any clinically significant gastrointestinal abnormality that may affect the intake, transit or absorption of the study drug, such as the inability to take medication in the form of oral tablets or solution. Presence of any psychiatric or cognitive impairment that limits understanding or the signing of the informed consent and/or compromises compliance with the requirements of this protocol. Significant or uncontrolled cardiovascular disease, including: 1. Myocardial infarction in the previous 12 months. 2. Uncontrolled angina in the previous 6 months. 3. Congestive heart failure in the previous 6 months. 4. Diagnosed or suspected congenital long QT syndrome. 5. History of ventricular arrhythmias of any clinically significant type (such as ventricular tachycardia, ventricular fibrillation or torsades de pointes). 6. QTc prolongation on an electrocardiogram prior to entry (\\>470 ms). 7. History of second- or third-degree heart block (these patients may be eligible if they carry pacemakers). 8. Heart rate \\<50/min on the baseline electrocardiogram. 9. Uncontrolled hypertension Any patient with a history of significant cardiovascular disease, even if it is currently controlled, or who presents signs or symptoms that suggest impaired left ventricular function according to the investigator should have an assessment of left ventricular ejection fraction (LVEF) by ECCO or MUGA. If the LVEF in these circumstances is below the site's lower limit of normality or less than 50%, the patient will not be eligible. History of any cancer, except in the following circumstances: Patients with a history of other malignancies are eligible if they have been disease-free for at least the last 3 years and if, in the investigator's opinion, there is a low risk of disease recurrence. People with the following cancers are eligible, even if they have been diagnosed and treated in the past 3 years: cervical carcinoma in situ and basal cell carcinoma. Patients will not be eligible if there is evidence of another cancer that required therapy other than surgery in the past 3 years."
        },
        {
          "nct_id": "NCT03529448",
          "section": "title",
          "text_snippet": "Phase Ib, Open-label, Multicenter, Intrapatient Dose-escalation Clinical Trial to Assess the Safety Profile of the TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma"
        }
      ],
      "expected_sections": [
        "eligibility.inclusion"
      ],
      "gold_answers": [
        "Patients must have at least 15 slides without staining or a tissue block (frozen or paraffin-embedded) available from a previous biopsy or surgery (tumour sample previously archived)."
      ],
      "nct_id": "NCT03529448",
      "query": "What tissue availability is required before enrolling in NCT03529448?",
      "status_code": 200
    },
    {
      "answer": "Recurrent Glioblastoma",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT05118776",
          "section": "title",
          "text_snippet": "A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma"
        },
        {
          "nct_id": "NCT05118776",
          "section": "condition",
          "text_snippet": "Recurrent Glioblastoma"
        },
        {
          "nct_id": "NCT05118776",
          "section": "eligibility.inclusion",
          "text_snippet": "1\\. Age \u226518 years old, both male and female; 2\\. Histologically confirmed glioblastoma; 3\\. Patients with glioblastoma who have failed standard treatment (surgery, Stupp regimen), were diagnosed by MRI and evaluated by RANO standard to support the first recurrence. Stupp regimen needs to complete at least 6 medication cycles."
        }
      ],
      "expected_sections": [
        "condition"
      ],
      "gold_answers": [
        "Recurrent Glioblastoma"
      ],
      "nct_id": "NCT05118776",
      "query": "Which condition does trial NCT05118776 focus on?",
      "status_code": 200
    },
    {
      "answer": "Caregivers: nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV)",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT06989086",
          "section": "eligibility.inclusion",
          "text_snippet": "Patients: Self-report a diagnosis of a primary malignant brain tumor (grade II-IV) \\>2 weeks post-cranial resection or biopsy Elevated Fear of Recurrence Distress Rating Primarily English speaking \\>/= 18 years of age at the time of enrollment Caregivers: nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV) Elevated Fear of Recurrence Distress Rating Primarily English speaking \\>/= 18 years of age at the time of enrollment"
        },
        {
          "nct_id": "NCT06989086",
          "section": "outcomes",
          "text_snippet": "{'measure': 'Feasibility - Study Enrollment', 'time_frame': 'From screening to randomization allocation'} {'measure': 'Feasibility - Study Retention at 12 Weeks', 'time_frame': 'From baseline assessment to 12 weeks'} {'measure': 'Feasibility - Study Retention at 24 Weeks', 'time_frame': 'From baseline assessment to 24 weeks'} {'measure': 'Feasibility - Sustained Eligibility (Delayed Treatment Control Arm Only)', 'time_frame': 'From baseline to 12-week assessment'} {'measure': 'Acceptability - Intervention', 'time_frame': 'From baseline to 12-week assessment in the Immediate Intervention arm; from 12-week assessment to 24-week assessment in the Delayed Treatment Control arm'} {'measure': 'Acceptability - Intervention', 'time_frame': 'From baseline to 12-week assessment in the Immediate Intervention arm; from 12-week assessment to 24-week assessment in the Delayed Treatment Control arm'} {'measure': 'Acceptability - Trial Procedures', 'time_frame': 'Week 24'} {'measure': 'Appropriateness - Interventionist Report', 'time_frame': 'At 12-week assessment in the Immediate Intervention arm; at 24-week assessment in the Delayed Treatment Control arm'}"
        },
        {
          "nct_id": "NCT06989086",
          "section": "condition",
          "text_snippet": "Primary Malignant Brain Tumor Glioblastoma (GBM) Astrocytoma Oligodendroglioma Caregiver"
        },
        {
          "nct_id": "NCT06989086",
          "section": "eligibility.exclusion",
          "text_snippet": "Patient / Caregiver Exclusion: Cognitive impairment that might prohibit active intervention engagement Inability to understand and provide informed consent Inability to attend virtual sessions due to unstable or no internet connection"
        }
      ],
      "expected_sections": [
        "eligibility.inclusion"
      ],
      "gold_answers": [
        "Caregivers: nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV)",
        "nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV)"
      ],
      "nct_id": "NCT06989086",
      "query": "In trial NCT06989086, who can enroll as caregivers?",
      "status_code": 200
    },
    {
      "answer": "MGMT promoter methylation status must be tested for all patients.",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT04765514",
          "section": "eligibility.inclusion",
          "text_snippet": "1. Newly-diagnosed, histologically proven, intracranial glioblastoma with maximal safe resection. Biopsy alone is expected if resection is not possible. MGMT promoter methylation status must be tested for all patients. 2. History and physical examination, including neurological examination, within 14 days prior to randomization. 3. Age \u2265 65 \\& KPS of 60 - 70 4. Stable or decreasing dose of corticosteroids for at least 14 days prior to randomization. 5. Laboratory evaluation within 7 days prior to randomization, with adequate function as defined below: 1. ANC \u2265 1.5 x 109/L 2. Platelets \u2265 100 x 109/L 3. Estimated Glomerular Filtration Rate (eGFR) \\> 59 4. Total serum bilirubin \u2264 30 umol/L (ie \u2264 1.5 times ULN) 5. ALT \\< 150 U/L (ie \\< 3 times ULN) 6. AST \\< 120 U/L (ie \\< 3 times ULN) 7. Alkaline phosphatase \\< 390 U/L (ie \\< 3 times ULN) 6. Patients must sign a study-specific informed consent prior to study registration. 7. Patients of childbearing / reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period and for a period of 6 months after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly. Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard. 1. This will apply for male patients only and their female partner if of child bearing potential. 2. Effective contraception should also be used by male patients taking temozolomide. Men being treated with temozolomide are advised not to father a child during or up to 6 months after discontinuation of treatment (male patients). 8. Male patients should agree to not donate sperm during the study treatment and for six months post treatment completion."
        },
        {
          "nct_id": "NCT04765514",
          "section": "interventions",
          "text_snippet": "OTHER: Biomarker based treatment (Temozolomide monotherapy or Radiotherapy monotherapy) COMBINATION_PRODUCT: Chemo-Radiotherapy consisting of 40 Gy in 15 daily fractions with concurrent temozolomide."
        },
        {
          "nct_id": "NCT04765514",
          "section": "title",
          "text_snippet": "A Randomized Controlled Trial of Chemo-Radiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail Patients With Newly Diagnosed Glioblastoma"
        }
      ],
      "expected_sections": [
        "eligibility.inclusion"
      ],
      "gold_answers": [
        "MGMT promoter methylation status must be tested for all patients."
      ],
      "nct_id": "NCT04765514",
      "query": "What biomarker testing is required in NCT04765514 before randomization?",
      "status_code": 200
    },
    {
      "answer": "Hypoxia mapping",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT06041555",
          "section": "outcomes",
          "text_snippet": "{'measure': 'Hypoxia mapping', 'time_frame': 'At the end of the sequence of treatment of each patient, that is 13 weeks after the beginning of the treatment'}"
        },
        {
          "nct_id": "NCT06041555",
          "section": "eligibility.inclusion",
          "text_snippet": "18years old or older diagnosed with prostate, kidney, cervix, head and neck cancer or glioblastoma indication of external radiotherapy treated with the Linac UNITY MRI guided radiotherapy at the centre hospitalier Lyon Sud des Hospices Civils de Lyon agreement of the patient to participate affiliated to a social security system"
        },
        {
          "nct_id": "NCT06041555",
          "section": "title",
          "text_snippet": "MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)"
        }
      ],
      "expected_sections": [
        "outcomes"
      ],
      "gold_answers": [
        "Hypoxia mapping"
      ],
      "nct_id": "NCT06041555",
      "query": "What outcome measure tracks the MRI sequence program in NCT06041555?",
      "status_code": 200
    },
    {
      "answer": "DRUG: Gliolan",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT05590689",
          "section": "interventions",
          "text_snippet": "DRUG: Gliolan RADIATION: Radiodynamic therapy"
        },
        {
          "nct_id": "NCT05590689",
          "section": "eligibility.inclusion",
          "text_snippet": "Written patient consent after comprehensive information Age \\>/= 18 years Recurrence of supratentorial glioblastoma after initial resection and adjuvant therapy (e.g. radio-chemotherapy, targeted therapies, antiangiogenic therapies as determined by the tumor board) (with planned second resection cohort 0 and 1), second or third recurrences permitted Clinically indicated further radiotherapy as per decision of the tumor board as part of therapy for recurrence Histological verification of recurrent glioblastoma independent of methylated MGMT promotor status when alkylating chemotherapy failed at this time. Karnofsky Performance Score \u2265 60 For female and male patients and their female partners of childbearing/reproductive potential(\\*): Willingness to apply highly effective contraception (Pearl index \\<1) during the entire study (and for at least 6 months after the first application of 5-ALA). Such methods include: 1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: I. oral II. intravaginal III. transdermal 2. progestogen only hormonal contraception associated with inhibition of ovulation: I. oral II. injectable III. implantable 3. intrauterine device (IUD) 4. intrauterine hormone-releasing system (IUS) 5. bilateral tubal occlusion 6. vasectomised partner 7. male patients have to use a condom 8. sexual abstinence Pre-menopausal(\\*) female patients with childbearing potential: a negative pregnancy test must be obtained max. 72h prior to treatment start Adequate liver function: bilirubin \\< 1.5 times above upper limit of normal range (ULN), alanine transaminase (ALT/SGPT) and aspartate transaminase (AST/SGOT) \\< 3 times ULN. In the case of documented or suspected Gilbert's disease bilirubin \\< 3 times ULN. Adequate renal function: creatinine \\< 3 times above ULN; eGFR \\>/= 60 ml/min, Blood clotting: INR/Quick/PT and PTT within acceptable limits according to the investigator. (\\*) Definition: A man is considered of reproductive potential after puberty unless permanently sterile by bilateral orchidectomy. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A post-menopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient."
        },
        {
          "nct_id": "NCT05590689",
          "section": "eligibility.exclusion",
          "text_snippet": "Patient unable to undergo imaging by MRI, PET or contrast-enhanced CT for whatever reason (e.g. pace-maker) Pregnant and breastfeeding women Past medical history of diseases with poor prognosis, e.g., severe coronary heart disease, heart failure (NYHA III/IV), severe and poorly controlled diabetes, immune deficiency, residual deficits after stroke, severe mental retardation or other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator) Any active infection (at the discretion of the investigator) Hypersensitivity against porphyrins Known diagnosis of porphyria Participation in another clinical trial with therapeutic intervention or use of any other therapeutic interventional agent other than the standard therapy since diagnosis of glioblastoma Known intolerance to study medication Pre-treatment with other potentially phototoxic or photosensitizing substances (e.g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts, products containing St. John's wort ) during the 2 weeks preceding RDT"
        }
      ],
      "expected_sections": [
        "interventions"
      ],
      "gold_answers": [
        "DRUG: Gliolan",
        "Gliolan"
      ],
      "nct_id": "NCT05590689",
      "query": "Which drug is paired with radiodynamic therapy in NCT05590689?",
      "status_code": 200
    },
    {
      "answer": "RADIATION: hypofractionated postoperative radiotherapy",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT06740955",
          "section": "interventions",
          "text_snippet": "RADIATION: hypofractionated postoperative radiotherapy RADIATION: Conventionally fractionated postoperative radiotherapy"
        },
        {
          "nct_id": "NCT06740955",
          "section": "title",
          "text_snippet": "A Randomized, Open, Controlled, Multi-center Clinical Trial of Hypofractionated Postoperative Radiotherapy for Adult Glioblastoma"
        },
        {
          "nct_id": "NCT06740955",
          "section": "eligibility.inclusion",
          "text_snippet": "1. Newly diagnosed glioblastoma confirmed by histopathology or molecular pathology; 2. Complete or partial tumor resection or biopsy via neurosurgery; 3. The age of signing the informed consent form was 18-70 years old, male or female; (4) KPS score \u226560; (5) expected survival time \u22656 months; 6\\. Radiotherapy should be started within 6 weeks after surgery; 7. Vital organ function meets the following requirements (excluding the use of any blood components and cell growth factors within 14 days) : Normal bone marrow reserve: white blood cell (WBC) \u22653.0\u00d7109/L, neutrophil count (NEUT) \u22651.5\u00d7109/L, platelet count (PLT) \u226580\u00d7109/L, hemoglobin (Hb) \u226590 g/L Normal renal function or serum creatinine (SCr) \u2264 1.5 times the upper limit of normal (ULN) or creatinine clearance \u226550 ml/ minute (Cockcroft-Gault equation) Normal liver function or total bilirubin (TBIL) \u2264 1.5 times the upper limit of normal (ULN) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level \u2264 2.5 times the upper limit of normal (ULN); 8. Able and willing to follow the study and follow-up procedures; 9. Men and women of childbearing potential must agree to use adequate contraception throughout the study and for 6 months after the end of treatment. Female subjects of childbearing potential were required to have a negative blood pregnancy test within 72 hours before the first dose. 10\\. The subjects voluntarily participated in this clinical study and signed the informed consent form. The compliance was good and the subjects could cooperate with the follow-up."
        }
      ],
      "expected_sections": [
        "interventions"
      ],
      "gold_answers": [
        "RADIATION: hypofractionated postoperative radiotherapy"
      ],
      "nct_id": "NCT06740955",
      "query": "What hypofractionated approach is being tested against conventional radiotherapy in NCT06740955?",
      "status_code": 200
    },
    {
      "answer": "Four Months",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT03451799",
          "section": "outcomes",
          "text_snippet": "{'measure': 'Safety of the intervention', 'time_frame': 'Four Months'} {'measure': 'Safety of the intervention', 'time_frame': 'Four months'}"
        },
        {
          "nct_id": "NCT03451799",
          "section": "eligibility.inclusion",
          "text_snippet": "Adults (age \u2265 18 years) Newly or recently diagnosed glioblastoma. Patients may enroll in the study from the time of diagnosis (prior to the initiation of standard-of-care chemoradiation) up until the initiation of post-radiation adjuvant chemotherapy (typically approximately 3-4 weeks after the completion of radiation therapy). Overall, this provides a window of approximately 3 months from the time of diagnosis for patients to enroll in this study. No recurrent glioblastoma is allowed on trial. Being seen for treatment of glioblastoma at Cedars-Sinai Medical Center. Note: Okay if patients receiving chemotherapy or radiation therapy at another facility Patients on low and managed doses of steroids are permitted. Up to 8 mg dexamethasone or steroid equivalent."
        },
        {
          "nct_id": "NCT03451799",
          "section": "eligibility.exclusion",
          "text_snippet": "Karnofsky Performance Status of \\<70 as deemed by physician or equivalent Body Mass Index of \\<22 kg/m2 (rounded to nearest integer) Patients with disorders that affect lipid metabolism such as pyruvate carboxylase deficiency, porphyria, primary carnitine deficiency, carnitine palmitoyltransferase I or II deficiency, carnitine translocase deficiency, Beta-Oxidation Defects Medical comorbidities that in the opinion of the investigator limits the patient's ability to complete this study Pregnant, nursing, or implanted with an intrauterine device (IUD) that is not MR compatible Patients who are vegan or vegetarian will be excluded, as the ketogenic diet includes foods that may interfere with these preferences Patients on high doses of steroids will be excluded Patients currently receiving experimental therapeutic therapy will be excluded from the trial. Note: Off-label therapy use is permitted Inability to adhere to the protocol Patients with history of allergic reactions to surgical steel or elastomer/rubber are excluded from the activity monitor portion of the study. Because the activity monitor uses a Bluetooth low energy Transceiver, individuals using pacemakers, implantable cardiac defibrillators, neuro-stimulation devices, cochlear implants, hearing aids, or other electronic medical equipment should also be excluded from wearing the activity monitor. They can still use the Aria scale to record weight. Patients with mechanically, magnetically, or electrically activated implants, such as cardiac pacemakers, neurostimulators, and infusion pumps, that are not magnetic resonance imaging/positron emission tomography (MRI/PET) compatible. Patients with ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial, aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged. Patients unable to tolerate MRI/PET imaging secondary to an inability to lie supine or severe claustrophobia as assessed by the treating physician or principal investigator. Patients unable to lie still, hold their breath, or follow imaging procedure instructions as assessed by the treating physician or PI. Patients whose most recent renal function test does not meet Cedars-Sinai Medical center standard of care MRI contrast protocol requirements (glomerular filtration rate \\<45ml/min). Patients with a known allergy to Fludeoxyglucose F18 (F18-FDG) radioactive tracer or gadolinium-based contrast agent. Patients with allergy to animal dander or animal-instigated asthma."
        }
      ],
      "expected_sections": [
        "outcomes"
      ],
      "gold_answers": [
        "Four Months",
        "Four months"
      ],
      "nct_id": "NCT03451799",
      "query": "For NCT03451799, how long is safety of the ketogenic diet monitored?",
      "status_code": 200
    },
    {
      "answer": "Grade 2 or grade 3 meningioma according to the WHO 2021 classification.",
      "answer_exact_match": false,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT06275919",
          "section": "eligibility.inclusion",
          "text_snippet": "Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted Patients capable of taking oral medication Subject is willing and able to adhere to the study visit schedule and other protocol requirements. Histological diagnosis of grade 2 or grade 3 meningioma according to the WHO 2021 classification Radiologically documented progression of any existing tumor with an estimated planar growth \\>25% (bidirectional) in the last 12 months or appearance of new lesions Ineligible for further surgery and/or radiotherapy at least 1 Measurable lesion (minimum 10 x 10mm) on baseline MRI Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 (or KPS \u00b370) Male or female \u2265 18 years of age Subjects must have life expectancy of at least 6 months Paraffin-embedded tumor tissue available (mandatory) Dosage of dexamethasone or equivalent steroid within 7 days prior the randomization \u22644mg/die Stable or decreasing dosage of steroids for 7 days prior to the randomization. Adequate cardiac function and adequate liver, renal and hematological function Subject must have the following laboratory values at screening within 14 days before starting Regorafenib: Absolute neutrophil count (ANC) \u2265 1.5 x 109/L without growth factor support for 7 days (14 days if subject received pegfilgrastim). Hemoglobin (Hgb) \u226510 g/dL Platelet count (plt) \u2265100x 109/L Serum potassium concentration within normal range, or correctable with supplements Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and serum glutamate pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) \u2264 3.0 x Upper Limit of Normal (ULN). Serum total bilirubin \u2264 1.5 x ULN Serum creatinine \u2264 1.5 x ULN or measured glomerular filtration rate (GFR) \u2265 50 mL/min/1.73 m2 using an exogenous filtration marker such as iohexol, inulin, 51Cr EDTA or 1125 iothalamate, or creatinine clearance of \u2265 50 mL/min using Cockroft-Gault equation. Serum albumin \\> 3.5 g/dL PT (or INR) and APTT within normal range For women who are not postmenopausal (i.e., \\< 2 years after last menstruation) or surgically sterile (absence of ovaries and/or uterus) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive device, or barrier method of contraception in conjunction with spermicidal jelly) during the Treatment period and for at least 6 months after the last dose of study drug. For male patients who are partners of premenopausal women: agreement to use a barrier method of contraception during the Treatment period and for at least 6 months after the last dose of study drug. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to participate. 19\\. Patients with measurable, progressive meningioma who received radiation therapy are potentially eligible but need to show evidence of progression at least 24 weeks from completion of radiation therapy."
        },
        {
          "nct_id": "NCT06275919",
          "section": "eligibility.exclusion",
          "text_snippet": "Prior antineoplastic therapy for meningioma Subject incapacitated to understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort) Are taking strong UGT1A9 inhibitors (e.g. mefenamic acid, diflunisal and niflumic acid) Receiving additional, concurrent, active therapy for Meningioma outside of the trial. Disease outside the brain (ie. spinal cord or bone or metastasis to a distant organ) Candidate for urgent palliative intervention for primary disease (e.g., impending herniation) as judged by the Investigator History of allergy or hypersensitivity to any of the study treatments or any of their excipients. In the presence of therapeutic intent to anticoagulate the patient:,INR or PT and aPTT not within therapeutic limits (according to the medical standard in the institution) Unable or unwilling to undergo brain MRI scans with intravenous (IV) gadolinium History of another malignancy in the previous 3 years, with a disease-free interval of\\< 3 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Serious, non-healing wound, ulcer, bone fracture, or abscess. Any cerebrovascular accident (including transient ischemic attacks) within the last 6 months prior to initiation of study treatment. Have an ongoing infection with severity of Grade 2 or above (CTCAE 5.0) Any hemorrhage or bleeding event that is \u2265 Grade 3 based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE), Grade 2 intracranial hemorrhage, or persistent thrombotic/embolic event within 4 weeks prior to the start of study medication. Uncontrolled or severe cardiac disease (e.g., history of unstable angina, myocardial infarction, coronary stenting, or bypass surgery within the last 6 months prior to initiation of study treatment), symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation), requirement for inotropic support or use of devices for cardiac conditions (e.g.,pacemakers/defibrillators), or hypertension (participants with systolic blood pressure\\[BP\\] of \\> 160 mmHg or diastolic BP of \\> 100 mmHg despite optimal medical management are to be excluded). History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, or symptomatic pleural effusion. Active, known, or suspected auto-immune disease, including systemic lupus erythematosus, Hashimotos thyroiditis, scleroderma, polyarteritis nodosa, or auto-immune hepatitis. Known history of hepatitis B, human immunodeficiency virus (HIV), or active hepatitis C infection requiring treatment with antiviral therapy. Note: HIV testing is not required in the absence of clinical suspicion. History of bleeding diathesis (irrespective of severity). Uncontrolled intercurrent illness including (e.g., symptomatic ascites), but not limited to ongoing or active infection. Persistent \u2265 Grade 3 Lipase (\\> 2.0 - 5.0 x upper limit of normal \\[ULN\\] with signs or symptoms; \\> 5.0 x ULN and asymptomatic). Persistent proteinuria \\> 3.5 g/24 hours measured by urine protein creatinine ratio from a random urine sample (\u2265 Grade 3, CTCAE 5.0) Have any malabsorbition condition Any condition that could make the subject noncompliant with the study procedures and/or study requirements, as judged by the Investigator (for example: cognitive impairment, psychiatric illness, etc)."
        },
        {
          "nct_id": "NCT06275919",
          "section": "title",
          "text_snippet": "Regorafenib for Recurrent Grade 2 and 3 Meningioma. A Multicenter, Randomized Phase II Study (MIRAGE Trial)"
        },
        {
          "nct_id": "NCT06275919",
          "section": "condition",
          "text_snippet": "Meningioma, Malignant"
        },
        {
          "nct_id": "NCT06275919",
          "section": "outcomes",
          "text_snippet": "{'measure': 'Progression free survival (PFS)', 'time_frame': 'Up to 36 months'}"
        }
      ],
      "expected_sections": [
        "eligibility.inclusion"
      ],
      "gold_answers": [
        "Histological diagnosis of grade 2 or grade 3 meningioma according to the WHO 2021 classification"
      ],
      "nct_id": "NCT06275919",
      "query": "What tumor grades must be documented for eligibility in NCT06275919?",
      "status_code": 200
    },
    {
      "answer": "RADIATION: Intensity-Modulated Radiation Therapy OTHER: Quality-of-Life",
      "answer_exact_match": false,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT03251027",
          "section": "title",
          "text_snippet": "Intensity-Modulated Stereotactic Radiotherapy as an Upfront Scalp-Sparing Intervention for the Treatment of Newly Diagnosed Grade II-IV Gliomas"
        },
        {
          "nct_id": "NCT03251027",
          "section": "interventions",
          "text_snippet": "RADIATION: Intensity-Modulated Radiation Therapy OTHER: Quality-of-Life"
        },
        {
          "nct_id": "NCT03251027",
          "section": "eligibility.exclusion",
          "text_snippet": "Prior history of scalp radiation or intolerance to standard course of radiation treatment Co-morbidities that would influence wound healing including diabetes (insulin dependent) or smoking (current ongoing use) Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception Karnofsky performance status (KPS) \\< 60 Patient can't have magnetic resonance imaging (MRI) scan Active collagen vascular disease"
        }
      ],
      "expected_sections": [
        "interventions"
      ],
      "gold_answers": [
        "RADIATION: Intensity-Modulated Radiation Therapy"
      ],
      "nct_id": "NCT03251027",
      "query": "Which radiation technique is delivered upfront in NCT03251027?",
      "status_code": 200
    },
    {
      "answer": "Must have histologically or cytologically confirmed glioblastoma multiforme prior to administration of the DRI \u03b3\u03b4 T cell injection.",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT04165941",
          "section": "eligibility.inclusion",
          "text_snippet": "Must have magnetic resonance imaging (MRI) features consistent with and suspicious for malignant glioma. This will be Part A - Tissue (biopsy) and Rickham catheter placement. Must have histologically or cytologically confirmed glioblastoma multiforme prior to administration of the DRI \u03b3\u03b4 T cell injection. This will be Part B - Screening and Study Treatment. Prior therapy: Must have completed a standard temozolomide and radiotherapy treatment as described in Part A and be eligible to receive maintenance therapy with temozolomide (consistent with NCCN guidelines for newly diagnosed GBM and maintenance therapy). Age \u226518 years\u03a6: Because no dosing or adverse event data are currently available on the use of \u03b3\u03b4 T cells in patients \\<18 years of age, children are excluded from this study but will be eligible for future pediatric Phase I single-agent trials. Karnofsky Performance Status \u226570% Life expectancy of greater than 12 weeks Patients must have organ and marrow function as defined below: 1. leukocytes \\>3,000/\u00b5l 2. absolute neutrophil count \\>1,500/\u00b5l 3. Hgb greater than or equal to 9.0 g/dL 4. platelets \\>100,000/\u00b5l 5. total bilirubin within normal institutional limits 6. AST (SGOT)/ALT (SGPT) \\<2.5 X institutional upper limit of normal 7. Normal electrolyte levels including sodium, calcium, potassium, chloride and magnesium 8. INR/PT/aPTT \u22641.5xULN 9. Normal EKG; if abnormal, NCS 10. Normal blood presure as adjusted for age Creatinine within normal institutional limits or if higher than the normal range, calculated creatinine clearance (CrCl) must be \u2265 50 mL/min/1.73 m2 (e.g., by Cockcroft-Gault formula); actual body weight must be used for CrCl unless body mass index (BMI) is \\> 30 kg/m2, in which case, lean body weight must be used"
        },
        {
          "nct_id": "NCT04165941",
          "section": "title",
          "text_snippet": "A Phase I Study of Drug Resistant Immunotherapy (DRI) with Activated, Gene Modified \u0393\u03b4 T Cells in Patients with Newly Diagnosed Glioblastoma Multiforme Receiving Maintenance Temozolomide Chemotherapy"
        },
        {
          "nct_id": "NCT04165941",
          "section": "eligibility.exclusion",
          "text_snippet": "Patients who have received any therapy for the treatment of GBM prior to inclusion in Part A and any treatment other than standard of care as described in Part A of this study including: cellular immunotherapy or gene therapy within 6 weeks prior to entering the study, surgical resection or alkylating agent chemotherapy within 4 weeks prior to entering the study, or have received experimental immunotherapy at any time, and those who have not recovered from adverse events due to therapeutic interventions administered more than 4 weeks earlier. Patients may not be receiving any other investigational agents. Contraindication to the placement of an intracranial access device (Rickham catheter) at the time of surgery. Prior history of encephalitis, multiple sclerosis, or other CNS infection Required steroid increase within 2 weeks of scheduled DRI \u03b3\u03b4 T cells administration. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any othermedical condition that precludes surgery. Also, psychiatric illness/social situations that would limit compliance with study requirements. Allergies/hypersensitivity: Aminobisphosphonates such as Zoledronate\u00ae, Pamidronate\u00ae or similar Pregnant women are excluded from this study because the lentiviral- modified \u03b3\u03b4 T cells designed to express MGMT cells have an unknown potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these cells, breastfeeding should be discontinued if the mother is treated with the lentiviral-modified \u03b3\u03b4 T cells designed to express MGMT. The following birth control methods are acceptable for this study in women of child- bearing potential: A Combination of TWO of the following: 1. Barrier method of contraception: 1. condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide 2. IUD 2. Hormone-based Contraceptive Note: Drug-drug interactions with some ARVs will make hormonal contraception a less reliable method. Because patients with immune deficiency will be unable to mount the anticipated immune response underlying this therapeutic rationale, HIV-seropositive patients are excluded from this study. Some of the contraceptive methods listed above may not prevent the spread of HIV to other people. Patients should discuss their contraceptive choices with their health care provider to choose the best way to both prevent pregnancy as required by this study and to prevent the spread of HIV to any partner(s). Patients with history of prior organ or bone marrow transplantation are not eligible."
        },
        {
          "nct_id": "NCT04165941",
          "section": "outcomes",
          "text_snippet": "{'measure': 'Primary: Highest safe dose frequency or maximally planned dose, if no dose-limiting toxicity observed.', 'time_frame': '12 weeks'}"
        }
      ],
      "expected_sections": [
        "eligibility.inclusion"
      ],
      "gold_answers": [
        "Must have histologically or cytologically confirmed glioblastoma multiforme prior to administration of the DRI \u03b3\u03b4 T cell injection."
      ],
      "nct_id": "NCT04165941",
      "query": "What confirmation is required before administering the DRI \u03b3\u03b4 T cell injection in NCT04165941?",
      "status_code": 200
    },
    {
      "answer": "DIAGNOSTIC_TEST: 18F-GE-180 PET",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT06113705",
          "section": "interventions",
          "text_snippet": "DIAGNOSTIC_TEST: 18F-GE-180 PET DIAGNOSTIC_TEST: Advanced MRI OTHER: Collection of hematopoietic stem cells OTHER: Blood withdrawal OTHER: Collection of Cancer Stem Cells"
        },
        {
          "nct_id": "NCT06113705",
          "section": "eligibility.inclusion",
          "text_snippet": "1. Patients of both sex and any race age \\>= 18. 2. Histologically proven glioblastoma multiforme wild type for IDH1-2 mutation with MGMT promoter methylated or unmethylated OR subjects with medical history, clinical sign and symptoms and MRI findings highly consistent with the diagnosis of IDH wild type glioblastoma. 3. Patient eligible to undergo treatment with TMZ and RT (Stupp protocol or hypofractionated protocol as per Institutional Multidisciplinary Brain Tumor Board's decision) 4. Willingness and ability to sign the informed consent and participate to the trial."
        },
        {
          "nct_id": "NCT06113705",
          "section": "outcomes",
          "text_snippet": "{'measure': 'Predictive models of pseudoprogression', 'time_frame': 'From baseline assessment to the last visit of the patient as per protocol'}"
        }
      ],
      "expected_sections": [
        "interventions"
      ],
      "gold_answers": [
        "DIAGNOSTIC_TEST: 18F-GE-180 PET",
        "18F-GE-180 PET"
      ],
      "nct_id": "NCT06113705",
      "query": "Which PET tracer is collected as part of the imaging regimen in NCT06113705?",
      "status_code": 200
    },
    {
      "answer": "Patients must have FGFR Amplification as determined via the MATCH Master Protocol.",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT06308822",
          "section": "eligibility.inclusion",
          "text_snippet": "Patients must have met applicable eligibility criteria in the Master MATCH Protocol EAY131/ NCI-2015-00054 prior to registration to treatment subprotocol. Patients must fulfill all eligibility criteria outlined in MATCH Master Protocol at the time of registration to treatment step (Step 1, 3, 5, 7). Patients must have FGFR Amplification as determined via the MATCH Master Protocol. Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block). Patients must not have known hypersensitivity to JNJ-42756493 (erdafitinib) or compounds of similar chemical or biologic composition. Patients with current evidence of corneal or retinal disorder/keratopathy are excluded. Patients must not be currently using medications that can elevate serum phosphorous and/or calcium levels. Medications that increase serum calcium should be avoided. Over the counter calcium supplements, antacids that contain calcium (Tums) and vitamin D supplements (cholecalciferol and ergocalciferol) should be avoided. Prescription medications including lithium, hydrochlorothiazide and chlorthalidone must be used with caution. Medications that increase serum phosphate should be avoided. Over the counter laxatives that contain phosphate such as Fleets oral or Fleets enema and Miralax should be avoided. Patients with a history of hyperphosphatemia will be excluded. Patients may not have received strong inhibitors or potent inducers of CYP3A within 2 weeks before the first dose of study treatment. Patients with inability to discontinue treatment with a strong CYP3A4 and/or CYP2C9 inhibitor or inducer prior to start of treatment are excluded. Patients who have previously received treatment with a FGFR-targeted inhibitor are excluded. Such inhibitors include AZD4547, BGJ398, BAY1163877 and LY2874455). Prior non-selective FGFR inhibitor treatment (e.g. Pazopanib, dovitinib, ponatinib, brivanib, lucitanib, lenvatinib) are allowed. Patients must not have any history of or current evidence of renal or endocrine alterations of calcium/phosphate homeostasis, or history of or current evidence of extensive tissue calcification (by evaluation of the clinician), including but not limited to, the soft tissue, kidneys, intestine, myocardium and lung with the exception of calcified lymph nodes and asymptomatic vascular calcification per investigators' judgment. Patients with transitional cell carcinoma of the bladder and /or urothelial tract are not eligible. These patients are encouraged to enroll in the ongoing disease-specific studies. Patients with impaired renal function (glomerular filtration rate \\[GFR\\] \\< 60 mL/min) are excluded. GFR should be assessed by direct measurement (i.e., creatinine clearance or ethyldediaminetetraacetate) or, if not available, by calculation from serum/plasma creatinine (Cockcroft-Gault formula). Patients with persistent phosphate level \\> upper limit of normal (ULN) during screening (within 14 days of treatment and prior to cycle 1 day 1) and despite medical management are excluded. Patients with a history of or current uncontrolled cardiovascular disease as stated below are excluded: Unstable angina, myocardial infarction, or known congestive heart failure class II-IV within the preceding 12 months; cerebrovascular accident or transient ischemic attack within the preceding 3 months, pulmonary embolism within the preceding 2 months. Any of the following: sustained ventricular tachycardia, ventricular fibrillation, Torsades de Pointes, cardiac arrest, Mobitz II second degree heart block or third degree heart block; known presence of dilated, hypertrophic, or restrictive cardiomyopathy. Patients with impaired wound healing capacity defined as skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions are excluded. Female subjects (of child-bearing potential and sexually active) must use medically acceptable methods of birth control (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of the study, and for 4 months after the last intake of study drug. Male subjects (with a partner of child-bearing potential) must use a condom with spermicide when sexually active and must not donate sperm from the first dose of study drug until 5 months after the last dose of study drug."
        },
        {
          "nct_id": "NCT06308822",
          "section": "title",
          "text_snippet": "MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients With Tumors With FGFR Amplifications"
        },
        {
          "nct_id": "NCT06308822",
          "section": "outcomes",
          "text_snippet": "{'measure': 'Objective Response Rate', 'time_frame': 'Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration'}"
        }
      ],
      "expected_sections": [
        "eligibility.inclusion"
      ],
      "gold_answers": [
        "Patients must have FGFR Amplification as determined via the MATCH Master Protocol."
      ],
      "nct_id": "NCT06308822",
      "query": "What biomarker must patients carry to join NCT06308822?",
      "status_code": 200
    },
    {
      "answer": "Glioblastoma",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT04306432",
          "section": "eligibility.exclusion",
          "text_snippet": "Glioblastoma Performance status 3-4 (Karnofsky Performances of 60 or less)"
        },
        {
          "nct_id": "NCT04306432",
          "section": "title",
          "text_snippet": "Cognitive Function After Radiation Therapy for Primary Brain Tumours"
        },
        {
          "nct_id": "NCT04306432",
          "section": "condition",
          "text_snippet": "Primary Brain Tumour Radiation Toxicity Cognitive Impairment"
        }
      ],
      "expected_sections": [
        "eligibility.exclusion"
      ],
      "gold_answers": [
        "Glioblastoma"
      ],
      "nct_id": "NCT04306432",
      "query": "Which diagnosis leads to exclusion from NCT04306432?",
      "status_code": 200
    },
    {
      "answer": "Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) With Microbubbles for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy",
      "answer_exact_match": true,
      "citation_match": true,
      "citations": [
        {
          "nct_id": "NCT04440358",
          "section": "title",
          "text_snippet": "Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) With Microbubbles for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy"
        },
        {
          "nct_id": "NCT04440358",
          "section": "eligibility.exclusion",
          "text_snippet": "Acute intracranial hemorrhage Ferrous metallic implanted objects in the skull or brain Prior toxicity with carboplatin chemotherapy Women who are pregnant or breastfeeding Cerebellar spinal cord or brain stem tumor Known active Hepatitis B or Hepatitis C or HIV Significant depression not adequately controlled Cardiac disease or unstable hemodynamics Severe hypertension History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage Active drug or alcohol use disorder Known sensitivity to gadolinium-based contrast agents Known sensitivity or contraindications to ultrasound contrast agent or perflutren Unable to undergo MRI or contraindications to MRI such as non-MRI compatible implanted devices Difficulty lying supine and still or severe claustrophobia which cannot be managed with medication Severely impaired renal function Right to left or bi-directional cardiac shunt Cranial or systemic infection requiring antibiotics Known additional malignancy that is progression or require active treatment"
        },
        {
          "nct_id": "NCT04440358",
          "section": "eligibility.inclusion",
          "text_snippet": "Must be between 18-80 years old Histologically confirmed glioblastoma Planned for Carboplatin monotherapy Be willing and able to provided written informed consent/assent Tumor progression after first line therapy Recovered to grade 0 or 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy Women of childbearing potential is confirmed not pregnant. Male and Female subjects utilize highly effective contraception Able to communicate verbally"
        },
        {
          "nct_id": "NCT04440358",
          "section": "outcomes",
          "text_snippet": "{'measure': 'Occurrence of Adverse Events', 'time_frame': 'Through study completion, an average of 12 months'} {'measure': 'Contrast intensity on MR imaging', 'time_frame': 'Immediately after Exablate BBBD procedure'}"
        },
        {
          "nct_id": "NCT04440358",
          "section": "interventions",
          "text_snippet": "DEVICE: Exablate BBBD DRUG: Carboplatin"
        },
        {
          "nct_id": "NCT04440358",
          "section": "condition",
          "text_snippet": "Recurrent Glioblastoma"
        }
      ],
      "expected_sections": [
        "title"
      ],
      "gold_answers": [
        "Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) With Microbubbles for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy"
      ],
      "nct_id": "NCT04440358",
      "query": "What is the official title of NCT04440358?",
      "status_code": 200
    }
  ],
  "metrics": {
    "answer_exact_match": {
      "accuracy": 0.7619047619047619,
      "correct": 16,
      "total": 21
    },
    "citation_section_match": {
      "accuracy": 1.0,
      "correct": 21,
      "total": 21
    },
    "error_count": 0,
    "total_examples": 21
  }
}
